Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

249.12 -1.12 (-0.45%)
Streaming Delayed Price Updated: 1:15 PM EDT, Aug 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - Ordinary Share

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target. 
Via Benzinga
News headline image
Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded mixed, with the Nasdaq gaining more than 50 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Ascendis Pharma's Program Hits Primary Goal In Children With Short-Limbed Dwarfism ↗
 
Via Benzinga
News headline image
Analyst Ratings for Ascendis Pharma ↗
Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
6 Analysts Have This to Say About Ascendis Pharma ↗
Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Opiant Pharma (NASDAQ:OPNT) stock rose 118.3% to $20.74 during Monday's pre-market session. The market value of their outstanding shares is at $107.1 million. As per the press release, Q3... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Expert Ratings for Ascendis Pharma ↗
Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings: 
Via Benzinga
News headline image
Expert Ratings for Ascendis Pharma ↗
Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND) within the last quarter: 
Via Benzinga
News headline image
What 14 Analyst Ratings Have To Say About Ascendis Pharma ↗
Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings: 
Via Benzinga
News headline image
Where Ascendis Pharma Stands With Analysts ↗
Over the past 3 months, 4 analysts have published their opinion on Ascendis Pharma (NASDAQ:ASND) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
News headline image
Ascendis Seeks FDA Nod For TransCon PTH In Adults With Hypoparathyroidism ↗
Ascendis Pharma (NASDAQ: ASND) has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon PTH, an investigational pro-drug designed to restore parathyroid... 
Via Benzinga
News headline image
Oppenheimer Maintains Outperform Rating for Ascendis Pharma: Here's What You Need To Know ↗
  Oppenheimer has decided to maintain its Outperform rating of Ascendis Pharma (NASDAQ:ASND) and lower its price target from $154.00 to $144.00. Shares of Ascendis Pharma are trading up 8.7% over the... 
Via Benzinga
News headline image
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Ascendis Slammed After Growth Hormone Drug Faces An Unexpected Challenge ↗
Ascendis Pharma sells a treatment for children with insufficient growth hormone. 
Via Investor's Business Daily
News headline image
Where Ascendis Pharma Stands With Analysts ↗
Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND 
Via Benzinga
News headline image
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
BofA Upgrades Ascendis Pharma After Promising TCP Phase 3 Data ↗
Following Ascendis Pharma’s (NASDAQ: ASND) reporting of positive topline Phase III data for its PaTHway trial of TransCon PTH (TCP) in adults with hypoparathyroidism, the... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022 ↗
Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Erytech Pharma (NASDAQ:ERYP) stock rose 18.7% to $1.65 during Monday's pre-market session. The market value of their outstanding shares is at $51.1 million.... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
Wells Fargo raised the price target on Laredo Petroleum, Inc. (NYSE: LPI) from $72 to $113. Laredo Petroleum shares fell 2.8% to $71.00 in pre-market trading. 
Via Benzinga
News headline image
Ascendis Pharma's Hypoparathyroidism Trial Meets Primary, Secondary Endpoints ↗
Ascendis Pharma A/S (NASDAQ: ASND) announced topline data from its Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism (HP), a condition in... 
Via Benzinga
News headline image
7 Biotech Stocks With Key Catalysts in March ↗
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. 
Via InvestorPlace
News headline image
Expert Ratings For Ascendis Pharma ↗
Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
News headline image
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis... 
Via Benzinga
News headline image
Pfizer Dives After FDA Rejects Its OPKO-Partnered Rare Disease Treatment ↗
Pfizer stock tumbled after the FDA rejected an OPKO-partnered drug. 
Via Investor's Business Daily
News headline image
Ascendis Pharma's Growth Hormone Deficiency Med Scores European Approval ↗
The European Commission (EC) has granted marketing authorization to Ascendis Pharma A/S's (NASDAQ: ASND) Lonapegsomatropin (developed under the name TransCon hGH).... 
Via Benzinga
News headline image
Earnings Scheduled For March 2, 2022 ↗
Companies Reporting Before The Bell • SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. •... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 ↗
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022 ↗
Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.